| Literature DB >> 24102972 |
L A Savory1, S J Griffin, K M Williams, A T Prevost, A-L Kinmonth, N J Wareham, R K Simmons.
Abstract
AIMS: To describe change in self-reported diet and plasma vitamin C, and to examine associations between change in diet and cardiovascular disease risk factors and modelled 10-year cardiovascular disease risk in the year following diagnosis of Type 2 diabetes.Entities:
Mesh:
Year: 2013 PMID: 24102972 PMCID: PMC4208684 DOI: 10.1111/dme.12316
Source DB: PubMed Journal: Diabet Med ISSN: 0742-3071 Impact factor: 4.359
Characteristics of ADDITION-Cambridge participants with complete data at baseline and 1-year follow-up (n = 736)
| Characteristics | Baseline | Missing data | One-year follow-up | Missing data |
|---|---|---|---|---|
| Socio-demographic | ||||
| Age, years | 61.1 (7.1) | 0/736 | – | – |
| Caucasian ethnicity, | 712 (96.7) | 0/736 | – | – |
| Occupation, | 16/736 | |||
| Managerial and professional | 248 (34.4) | – | – | |
| Intermediate | 165 (22.9) | – | – | |
| Routine and manual | 307 (42.6) | |||
| Health behaviours | ||||
| Current smoker, | 125 (17.0) | 0/736 | 108 (14.9) | 12/736 |
| Median (interquartile range) alcohol intake, units/week | 3 (0–10) | 11/736 | 3 (0–9) | 19/736 |
| Self-reported total physical activity, metabolic equivalent h/day | 29.4 (9.8) | 0/736 | 29.5 (10.0) | 11/736 |
| Prescribed medication | ||||
| Lipid-lowering medication, | 172 (23.4) | 0/736 | 404 (55.4) | 7/736 |
| Anti-hypertensive medication, | 408 (55.4) | 0/736 | 485 (66.5) | 7/736 |
| Glucose-lowering medication, | 2 (0.3) | 0/736 | 220 (30.2) | 7/736 |
| Clinical variables | ||||
| BMI, kg/m2 | 33.4 (5.6) | 4/736 | 32.3 (5.6) | 3/736 |
| Waist circumference, cm | ||||
| Men | 114.2 (12.9) | 0/453 | 111.4 (12.9) | 2/453 |
| Women | 107.5 (13.0) | 1/283 | 103.9 (13.0) | 1/283 |
| Systolic blood pressure, mmHg | 141.7 (19.9) | 2/736 | 136.3 (18.5) | 4/736 |
| Total cholesterol, mmol/l | 5.4 (1.1) | 16/736 | 4.5 (1.0) | 3/736 |
| HDL cholesterol, mmol/l | 1.19 (0.33) | 16/736 | 1.22 (0.34) | 3/736 |
| HbA1c, mmol/mol | 56 | 18/736 | 48 | 10/736 |
| HbA1c,% | 7.3 (1.7) | 18/736 | 6.5 (0.9) | 10/736 |
| Modelled 10-year cardiovascular disease risk,% | 30.9 (14.5) | 23/650 | 25.5 (12.7) | 35/650 |
| Plasma vitamin C, μmol/l | 52.7 (22.3) | 75/736 | 54.4 (23.9) | 27/736 |
| Self-reported dietary intake | ||||
| Energy intake, kcal/day | 1943 (684) | 4/736 | 1693 (559) | 17/736 |
| Median (interquartile range) energy intake, kcal/day | 1840 (1493–2339) | 4/736 | 1622 (1316–2012) | 17/736 |
| Fruit intake, g/day | 252.9 (213.6) | 35/736 | 298.6 (216.9) | 44/736 |
| Median fruit intake, g/day | 210.7 (109.1–336.9) | 35/736 | 255.9 (149.7–396.4) | 44/736 |
| Vegetable intake, g/day | 211.5 (123.9) | 38/736 | 234.4 (140.7) | 56/736 |
| Median (interquartile range) vegetable intake, g/day | 188.1 (127.1–266.2) | 38/736 | 210.0 (145.6–291.2) | 56/736 |
| Fruit and vegetable intake (combined), g/day | 461.9 (271.9) | 65/736 | 529.5 (287.8) | 79/736 |
| Median (interquartile range) fruit and vegetable intake (combined), g/day | 407.1 (270.9–586.3) | 65/736 | 483.1 (344.8–658.3) | 79/736 |
| Fat,% of total energy intake | 32.2 (6.2) | 4/736 | 30.6 (6.2) | 17/736 |
| Median (interquartile range) fat,% of total energy intake | 32.4 (28.1–36.4) | 4/736 | 30.7 (26.3–34.9) | 17/736 |
| Englyst fibre [non-starch polysaccharides (NSP)] intake, g/day | 16.9 (6.7) | 4/736 | 18.3 (7.4) | 17/736 |
| Median (interquartile range) englyst fibre (NSP) intake, g/day | 15.9 (12.2–20.1) | 4/736 | 17.3 (13.4–21.6) | 17/736 |
| Sodium intake, mg/day | 2782 (1083) | 4/736 | 2661 (1042) | 14/736 |
| Median (interquartile range) sodium, g/day | 2.7 (2.0 to 3.3) | 4/736 | 2.5 (2.0–3.2) | 14/736 |
All values are means (sd) unless otherwise indicated.
P < 0.05 from McNemar’s test for categorical variables, paired t-test for normally distributed continuous variables and Wilcoxon signed rank test for non-normally distributed continuous variables for baseline vs. follow-up (separately in men and women).
Participants with a prior cardiovascular disease event (n = 86) were excluded.
Association between change in dietary intake, cardiovascular disease risk factors and modelled cardiovascular disease risk at 1-year follow-up in the ADDITION-Cambridge trial cohort*†
| BMI (kg/m2) | Waist circumference (cm) | Systolic blood pressure (mmHg) | HbA1c (mmol/mol) | Total cholesterol (mmol/mol) | HDL cholesterol (mmol/l) | Ten-year modelled cardiovascular disease risk (mmol/mol) | |
|---|---|---|---|---|---|---|---|
| ∆ Fruit intake (80 g/day) | –0.132 (–0.302 to 0.037) | –0.414 (–0.816 to –0.012) | 0.309 (–0.260 to 0.878) | –0.040 (–0.066 to –0.013) | –0.036 (–0.065 to –0.006) | –0.011 (–0.022 to 0.001) | 0.001 (–0.002 to 0.009) |
| ∆ Vegetable intake (80 g/day) | 0.620 (0.323 to 0.918) | 1.180 (0.456 to 1.905) | –0.470 (–1.547 to 0.608) | 0.000 (–0.050 to 0.048) | 0.035 (–0.020 to 0.091) | –0.014 (–0.035 to 0.007) | 0.002 (–0.003 to 0.008) |
| ∆ Fat intake (% of total energy intake) | 0.005 (–0.067 to 0.077) | 0.039 (–0.131 to 0.209) | 0.004 (–0.245 to 0.253) | 0.012 (0.001 to 0.023) | 0.013 (–0.001 to 0.026) | –0.001 (–0.006 to 0.004) | 0.001 (0.000 to 0.002) |
| ∆ Energy intake (100 kcal/day) | 0.078 (–0.008 to 0.164) | 0.207 (0.005 to 0.409) | –0.026 (–0.314 to 0.261) | 0.010 (–0.004 to 0.023) | 0.009 (–0.006 to 0.024) | –0.002 (–0.008 to 0.003) | 0.001 (0.000 to 0.003) |
| ∆ Plasma vitamin C (μmol) | –0.028 (–0.048 to –0.007) | –0.102 (–0.151 to –0.054) | –0.046 (–0.118 to 0.026) | –0.004 (–0.007 to 0.000) | –0.003 (–0.007 to 0.001) | 0.001 (–0.000 to 0.003) | –0.001 (–0.001 to 0.000) |
| ∆ Englyst fibre [non-starch polysaccharides (NSP)] intake, g/day | 0.005 (–0.060 to 0.070) | –0.044 (–0.198 to 0.110) | –0.059 (–0.277 to 0.160) | –0.005 (–0.014 to 0.006) | –0.002 (–0.014 to 0.010) | –0.002 (–0.007 to 0.003) | 0.000 (–0.001 to 0.002) |
| ∆ Sodium intake, g/day | 0.307 (–0.140 to 0.754) | 0.689 (–0.364 to 1.743) | 0.190 (–1.318 to 1.700) | 0.046 (–0.025 to 0.117) | 0.087 (0.008 to 0.166) | –0.013 (–0.044 to 0.017) | 0.008 (0.001 to 0.016) |
All models are adjusted for age, sex, trial group, socio-economic status, baseline phenotype, change in total physical activity, change in alcohol intake, change in smoking and change in medication (where relevant).
Fat intake models also include energy intake as a covariate.